Webinars » CGT » Webinar - The Industrialization of In Vivo CAR-T Therapy Development

Webinar - The Industrialization of In Vivo CAR-T Therapy Development

CAR-T therapies have revolutionized blood cancer treatment, but traditional ex vivo manufacturing remains costly and time-consuming. Next-generation in vivo CAR-T is set to change the game, driven by two delivery platforms: LVV (viral) and LNP (non-viral). Join our online webinar to explore how LVV and mRNA-tLNP are accelerating the industrialization of in vivo CAR-T therapies.

  • Chunling Xuan

    Chunling Xuan
    Director, LVV PD, ProBio

  • Jiang Xu

    Jiang Xu
    Head of LNP formulation, ProBio

Time Topic
15:30-16:15 Lentiviral Vector Process Development for In Vivo CAR-T: Key Points and Core Challenges
Dr. Chunling Xuan, Director, LVV PD, ProBio
  • Insights into process development challenges.
  • Key considerations in quality control and consistency.
  • Regulatory expectations and technical strategies for compliance.
16:15-17:00 mRNA-tLNP for In Vivo CAR-T: Challenges and Solutions
Dr. Jiang Xu, Head of LNP formulation, ProBio
  • Practical experience in developing CMC processes for mRNA-tLNP.
  • Analytical method development and optimization.
  • Latest biological data and findings from experimental validation.

Related service: LVV Drug Product One-Stop Solution, RNA-tLNP One-Stop Solution

Available materials

«
Previous Page
ProBio Announces New Executive Appointments
Next Page
ProBio Accelerates Chimagen's Global Market Expansion, Paving the Way for Innovative Antibody Therapy
»
  • Contact us
  • Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188
  • Fax: 1-732-210-0262